The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)

Robert T Chen; Baevin Carbery; Lisa Mac; Kenneth I Berns; Louisa Chapman; Richard C Condit; Jean-Louis Excler; Marc Gurwith; Michael Hendry; Arifa S Khan; Najwa Khuri-Bulos; Bettina Klug; James S Robertson; Stephen J Seligman; Rebecca Sheets; Anna-Lise Williamson; V3SWG

doi:10.1016/j.vaccine.2014.09.035

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)

Vaccine. 2015 Jan 1;33(1):73-5. doi: 10.1016/j.vaccine.2014.09.035. Epub 2014 Oct 8.

Authors

Robert T Chen¹, Baevin Carbery², Lisa Mac³, Kenneth I Berns⁴, Louisa Chapman³, Richard C Condit⁴, Jean-Louis Excler⁵, Marc Gurwith⁶, Michael Hendry³, Arifa S Khan⁷, Najwa Khuri-Bulos⁸, Bettina Klug⁹, James S Robertson¹⁰, Stephen J Seligman¹¹, Rebecca Sheets¹², Anna-Lise Williamson¹³; V3SWG

Collaborators

V3SWG:
Edward B Hayes, Marian P Laderoute, Brian Mahy, Andre Nahmias, Christina Via

Affiliations

¹ DHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA. Electronic address: brightoncollaborationv3swg@gmail.com.
² DHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
³ DHAP, NCHHSTP, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.
⁴ Department of Molecular Genetics and Microbiology, University of Florida College of Medicine, P.O. Box 100266, Gainesville, FL 32610, USA.
⁵ International AIDS Vaccine Initiative, New York, NY, USA; U.S. Military HIV Research Program (MHRP), Bethesda, MD 20817, USA.
⁶ PaxVax, San Diego, CA 92121, USA.
⁷ Laboratory of Retroviruses, Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, USA.
⁸ Division of Infectious Disease, Jordan University Hospital, Amman, Jordan.
⁹ Paul-Ehrlich-Institut, 63225 Langen, Germany.
¹⁰ Independent Adviser (formerly of National Institute for Biological Standards and Control, Potters Bar, EN6 3QG, UK).
¹¹ Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA.
¹² Division of AIDS, National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health, Bethesda, MD 20892, USA.
¹³ Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Service, Cape Town, South Africa.

Abstract

Recombinant viral vectors provide an effective means for heterologous antigen expression in vivo and thus represent promising platforms for developing novel vaccines against human pathogens from Ebola to tuberculosis. An increasing number of candidate viral vector vaccines are entering human clinical trials. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to improve our ability to anticipate potential safety issues and meaningfully assess or interpret safety data, thereby facilitating greater public acceptance when licensed.

Keywords: Immunization; Safety; Vaccines; Viral Vector.

Published by Elsevier Ltd.

MeSH terms

Clinical Trials as Topic
Drug Carriers / adverse effects*
Drug-Related Side Effects and Adverse Reactions / prevention & control*
Genetic Vectors*
Humans
International Cooperation*
Vaccines, Synthetic / adverse effects
Vaccines, Synthetic / genetics
Vaccines, Synthetic / immunology
Viral Vaccines / adverse effects*
Viral Vaccines / genetics
Viral Vaccines / immunology

Substances

Drug Carriers
Vaccines, Synthetic
Viral Vaccines

Grants and funding

CC999999/Intramural CDC HHS/United States